953039-63-9

Basic information

• Product Name: 8-BroMo-2-chloro-6-fluoro-quinazoline
• Synonyms: 8-BroMo-2-chloro-6-fluoro-quinazoline
• CAS NO: 953039-63-9
• Molecular Formula: C₈H₃BrClFN₂
• Molecular Weight: 261.4782232
• Mol File: 953039-63-9.mol
• Article Data: 6

Chemical Properties

• Boiling Point: 308.8±35.0 °C(Predicted)
• Appearance: /Solid
• Density: 1.836
• Storage Temp.: Inert atmosphere,Store in freezer, under -20°C
• PKA: -1.75±0.30(Predicted)
• CAS DataBase Reference: 8-BroMo-2-chloro-6-fluoro-quinazoline(CAS DataBase Reference)
• NIST Chemistry Reference: 8-BroMo-2-chloro-6-fluoro-quinazoline(953039-63-9)
• EPA Substance Registry System: 8-BroMo-2-chloro-6-fluoro-quinazoline(953039-63-9)

Safety Data

• Hazardous Substances Data: 953039-63-9(Hazardous Substances Data)

Usage

General Description

8-Bromo-2-chloro-6-fluoro-quinazoline is a specialized chemical compound belonging to the class of quinazolines. Quinazolines are compounds containing a 2-azabicyclo[2.2.2]octane moiety with three nitrogen atoms at the 1-, 3-, and 4- positions. 8-Bromo-2-chloro-6-fluoro-quinazoline is further characterized by specific halogens: a bromine atom at the 8- position, a chlorine atom at the 2- position, and a fluorine atom at the 6- position. It is not commonly found in nature and is typically used in laboratory settings, such as in research on new pharmaceuticals and other synthetic compounds. Due to its specific structure and properties, it may be utilized in chemical reactions of considerable interest in synthetic chemistry and medicinal chemistry.

Upstream product

• 259269-84-6 2-amino-3-bromo-5-fluorobenzoic acid 
• 55414-45-4 (2-amino-3-bromo-5-fluorophenyl)methanol 
• 953039-61-7 2-amino-3-bromo-5-fluorobenzaldehyde 
• 953039-62-8 8-bromo-6-fluoro-quinazolin-2-ol 
• 446-08-2 2-amino-5-fluorobenzoic acid 

Relevant articles and documents

METHODS OF CULTURING AND/OR EXPANDING STEM CELLS AND/OR LINEAGE COMMITTED PROGENITOR CELLS USING AMIDO COMPOUNDS

Provided are methods for expanding stem cells and/or lineage committed progenitor cells, such as hematopoietic stems cells and/or lineage committed progenitor cells, at least in part, by using compounds that antagonize AhR. The compounds are represented by formulae (I) (II) (III) (IV), wherein the letters and symbols a, b, c, d, e, f, g, Z, R1b, R2a and R2b have the meanings provided in the specification. Also provided are compositions comprising stem cells and/or lineage committed progenitor cells expanded by methods disclosed herein and methods for the treatment of diseases treatable by same.

CONDENSED-RING PYRIMIDYLAMINO DERIVATIVE, PREPARATION METHOD THEREFOR, AND INTERMEDIATE, PHARMACEUTICAL COMPOSITION AND APPLICATIONS THEREOF

Disclosed are a condensed-ring pyrimidylamino derivative, a preparation method therefor, and an intermediate, a pharmaceutical composition and applications thereof. The method for preparing the condensed-ring pyrimidylamino derivative comprises: in a solvent, in the presence of a palladium-containing catalyst, allowing a compound represented by formula I-a and a compound represented by formula I-b' to have a coupling reaction, and then preparing a compound represented by formula I by means of a deprotection reaction. Also disclosed applications of the condensed-ring pyrimidylamino derivative in the preparation of drugs for preventing, relieving and/or treating tumors or diseases caused by an anaplastic lymphoma kinase. The condensed-ring pyrimidylamino derivative of the present invention has an obvious restraint effect on the anaplastic lymphoma kinase.

Substituted piperazine compounds, application method and applications thereof

The invention discloses substituted piperazine compounds, an application method and applications thereof. Specifically, the invention relates to piperazine compounds and pharmaceutical compositions thereof for inhibiting reuptake of 5-hydroxytryptamine and/or stimulation of 5-HT1A acceptor. The invention also relates to a preparation method of the compounds and pharmaceutical compositions thereof, and an application of the compounds and pharmaceutical compositions thereof in the treatment of central nervous system dysfunction.